SENS

In the past six months, Senseonics reported strong Q1 2026 financial results with $11.7 million revenue and a 59% gross profit margin, raising over $100 million and launching Eversense 365 in Europe. A public offering in May 2026 generated $92.0 million but caused significant dilution. Real-world evidence for Eversense 365 was presented in June and September 2026, demonstrating strong performance. Q2 2026 earnings showed revenue of $14.5 million, surpassing estimates, despite EPS missing expectations and a widened net loss. Following Q2, the company raised its full-year 2026 revenue guidance to $62 million to $66 million. An independent director purchased additional shares in August 2026, and in September 2026, Senseonics announced a partnership with Beta Bionics to integrate Eversense 365 with their automated insulin delivery systems, with a Q4 2026 commercial launch anticipated.